Se solicita #médico #patólogo/a para #Tesis #octoral

Tema “Desarrollo de nuevos #biomarcadores en #cáncer de # mama”.

El candidato seleccionado recibirá entrenamiento en distintas técnicas de biología molecular y en la elaboración de trabajos científicos que le permitirán alcanzar el grado de Doctor (PhD) en Medicina.

Requisitos:            - Preferentemente con 4 años de experiencia (Residencia, Especialista, Concurrencia, Adscripto al Servicio o similar)

                       - Hasta 12 años de recibido

Lugar: Laboratorio de Mecanismos Moleculares de Carcinogénesis, Instituto de Biología y Medicina Experimental, Vuelta de Obligado 2490.

Enviar CV a la Dra. Patricia V. Elizade: pvelizalde@gmail.com

Ultimas publicaciones relacionadas con el tema:

Heregulin Co-opts PR Transcriptional Action Via Stat3 Role As a Coregulator to Drive Cancer Growth.

Proietti CJ, Izzo F, Díaz Flaqué MC, Cordo Russo R, Venturutti L, Mercogliano MF, De Martino M, Pineda V, Muñoz S, Guzmán P, Roa JC, Schillaci R, Elizalde PV.

Mol Endocrinol. 2015 Oct;29(10):1468-85. doi: 10.1210/me.2015-1170.

Stat3 regulates ErbB-2 expression and co-opts ErbB-2 nuclear function to induce miR-21 expression, PDCD4 downregulation and breast cancer metastasis.

Venturutti L, Romero LV, Urtreger AJ, Chervo MF, Cordo Russo RI, Mercogliano MF, Inurrigarro G, Pereyra MG, Proietti CJ, Izzo F, Díaz Flaqué MC, Sundblad V, Roa JC, Guzmán P, Bal de Kier Joffé ED, Charreau EH, Schillaci R, Elizalde PV.

Oncogene. 2015 Jul 27. doi: 10.1038/onc.2015.281. [Epub ahead of print]

Targeting ErbB-2 nuclear localization and function inhibits breast cancer growth and overcomes trastuzumab resistance.

Cordo Russo RI, Béguelin W, Díaz Flaqué MC, Proietti CJ, Venturutti L, Galigniana N, Tkach M, Guzmán P, Roa JC, O'Brien NA, Charreau EH, Schillaci R, Elizalde PV.

Oncogene. 2015 Jun;34(26):3413-28. doi: 10.1038/onc.2014.272.

Progesterone receptor assembly of a transcriptional complex along with activator protein 1, signal transducer and activator of transcription 3 and ErbB-2 governs breast cancer growth and predicts response to endocrine therapy.

Díaz Flaqué MC, Galigniana NM, Béguelin W, Vicario R, Proietti CJ, Russo R, Rivas MA, Tkach M, Guzmán P, Roa JC, Maronna E, Pineda V, Muñoz S, Mercogliano M, Charreau EH, Yankilevich P, Schillaci R, Elizalde PV.

Breast Cancer Res. 2013 Dec 17;15(6):R118. doi: 10.1186/bcr3587.

Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development.

Rivas MA, Venturutti L, Huang YW, Schillaci R, Huang TH, Elizalde PV. Breast Cancer Res. 2012 May 14;14(3):R77.

Clinical relevance of ErbB-2/HER2 nuclear expression in breast cancer.

Schillaci R, Guzmán P, Cayrol F, Beguelin W, Díaz Flaqué MC, Proietti CJ, Pineda V, Palazzi J, Frahm I, Charreau EH, Maronna E, Roa JC, Elizalde PV. BMC Cancer. 2012 Feb 22;12:74.

Progesterone receptor induces ErbB-2 nuclear translocation to promote breast cancer growth via a novel transcriptional effect: ErbB-2 function as a coactivator of Stat3.

Béguelin W, Díaz Flaqué MC, Proietti CJ, Cayrol F, Rivas MA, Tkach M, Rosemblit C, Tocci JM, Charreau EH, Schillaci R, Elizalde PV. Mol Cell Biol. 2010 Dec;30(23):5456-72. Epub 2010 Sep 27